Title:Effect of Iron Deficiency Anemia on Blood Glucose and Insulin
Resistance in Women with Type II Diabetes: A Single-group, Clinical
Interventional Study
Volume: 19
Issue: 3
Author(s): Mahmoud Parham, Gholam Reza Tavasoli, Shahram Arsang-Jang, Mohammad Amin Habibi, Davood Olad Dameshgi, Mohammad Reza Pashaei, Sajjad Ahmadpour*Jamshid Vafaeimanesh*
Affiliation:
- Patient Safety Research Center, Clinical
Research Institute, Urmia University of Medical Sciences, Urmia, Iran
- Clinical Research Development Center, Qom University of Medical Sciences, Qom, Iran
Keywords:
Iron deficiency anemia, type 2 diabetes mellitus, insulin resistance, hemoglobin A1C, fasting blood glucose.
Abstract:
Aims: Iron deficiency anemia (IDA) is one of the disorders recently associated with an
increase in insulin resistance (IR) and, consequently, diabetes mellitus (DM) affection by causing
oxidative stress. In this study, we look at how IDA may contribute to developing type II diabetes
mellitus (T2DM), controlling diabetes, and reducing IR in women with T2DM.
Methods: In this single group, clinical interventional study, we enrolled 40 women with T2DM
and IDA. Before and after intervention with ferrous sulfate tablets, their blood glucose (BG) levels
and IR levels were evaluated. This study was approved by the Ethics Committee of Qom University
of Medical Sciences (ethics code: IR.MUQ.REC.1397.031) and registered at the Iranian
Center for Clinical Trials (No. IRCT20170215032587N3). A significant level was considered p
<0.05.
Result: The mean age of patients was 48.18 ± 4.6 years, with 5.3-5.8 years duration of T2DM. After
the intervention, the mean fasting blood glucose (FBG) level reached 198.53 ± 48.11 to 170.93
± 37.41, which was significant (p <0.0001). Also, hemoglobin A1C level reached from 8.49 ± 0.9
to 7.96 ± 0.58, which was significant (p <0.0001). Homeostatic Model Assessment of Insulin Resistance
(HOMA-IR) demonstrating a significant reduction of IR levels after intervention with ferrous
sulfate tablets (p <0.018).
Conclusions: IDA treatment in patients with T2DM can significantly reduce the BG and IR levels.
To better control BG, checking iron status and its correction may provide better clinical outcomes
in these patients.
